Hydrix recently undertook a market research initiative focusing on the in-vitro diagnostics/point-of-care (IVD/POC) market, engaging with key stakeholders in the…
Safety–critical design engineering underpins many of the products and processes used in high-assurance applications. Hydrix’s track record extends to 20+…
Hydrix is pleased to announce it has joined the Ventri Clinical network, Australia’s Gateway for Cardiovascular Medtech Innovation. Facilitated by the Australian…
ASX ANNOUNCEMENT 28/06/2021 AngelMed receives USA FDA approval for the Guardian® device. Hydrix to submit local regulatory approval applications.Key Highlights:…
ASX ANNOUNCEMENT 01/10/2020 Implantation of Next-Generation AngelMed Guardian® commences in USKey Highlights: AngelMed announces first US implant of next-generation AngelMed…